Lexicon Pharmaceuticals LXRX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$1.04M+93.3% | -$15.53M-21.6% | -$12.77M-493% | $3.25M+113% | -$25.3M+25.1% | ||
| $110K-6.8% | $118K-21.9% | $151K-14.2% | $176K0.0% | $176K+40.8% | ||
| $3.08M+8.6% | $2.84M-17.7% | $3.44M+7.8% | $3.2M+5.0% | $3.04M+98.0% | ||
| $681K+37.6% | $495K+23.1% | $402K0.0% | $402K+0.2% | $401K0.0% | ||
| $9.4M— | —— | —— | -$264K+74.3% | -$1.03M-278% | ||
| -$5K-104% | $123K+1,330% | -$10K+69.7% | -$33K-10.0% | -$30K+92.6% | ||
| -$6.9M-22.1% | -$5.65M+59.7% | -$14M— | —— | -$21.69M-338% | ||
| $319K+129% | -$1.08M— | —— | —— | -$1.21M+44.2% | ||
| $581K+256% | $163K+806% | $18K-14.3% | $21K-98.6% | $1.54M+565% | ||
| -$14.73M+14.5% | -$17.23M+27.7% | -$23.83M— | —— | -$43.78M-104% | ||
| $105.96M+378% | $22.17M-17.0% | $26.73M+2.9% | $25.97M-60.0% | $64.97M+152% | ||
| $35.7M+32.2% | $27M-65.8% | $78.85M+90.2% | $41.46M-60.7% | $105.55M+31.9% | ||
| -$70.26M-1,555% | $4.83M-90.7% | $52.13M+237% | $15.48M-61.8% | $40.58M— | ||
| $5M+66.7% | $3M— | $0-100% | $45M— | $0— | ||
| $69.99M— | $0— | $0— | $0— | $0— | ||
| $2.84M— | —— | —— | —— | $572K— | ||
| $26.55M— | $0— | $0— | $0— | $0— | ||
| $88.76M+3,132% | -$2.93M— | $0+100% | -$45M-7,767% | -$572K— | ||
| $3.76M+125% | -$15.33M-154% | $28.29M+326% | -$12.52M-232% | -$3.77M-112% | ||
| $1.48M-12.3% | $1.69M-4.1% | $1.76M-8.5% | $1.92M-35.3% | $2.97M-5.0% | ||
| $562K+27.7% | $440K-39.9% | $732K-39.7% | $1.21M-8.4% | $1.33M-29.7% | ||
| $681K+37.6% | $495K+23.1% | $402K0.0% | $402K+0.2% | $401K0.0% | ||
| -$195K-2.6% | -$190K+0.5% | -$191K-0.5% | -$190K-2.2% | -$186K+70.9% | ||
| $319K+129% | -$1.08M— | —— | —— | -$1.21M+44.2% | ||
| $581K+256% | $163K+806% | $18K-14.3% | $21K-98.6% | $1.54M+565% | ||
| $35.7M+32.2% | $27M-65.8% | $78.85M+90.2% | $41.46M-60.7% | $105.55M+31.9% | ||
| $26.55M— | $0— | $0— | $0— | $0— | ||
| $65K-11.0% | $73K— | $0— | $0— | $0— | ||
| $5M+66.7% | $3M— | $0-100% | $45M— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Lexicon Pharmaceuticals generate?
- Lexicon Pharmaceuticals (LXRX) generated -$99.6M in operating cash flow over the trailing twelve months.
- Where does Lexicon Pharmaceuticals's cash flow data come from?
- Every line is extracted from Lexicon Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
